Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
Inventiva Is Maintained at Buy by Canaccord Genuity
Inventiva Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 8 07:54 ET
Express News | Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $20
Moomoo 24/7Apr 8 07:44 ET
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TipRanksApr 8 07:30 ET
Inventiva's Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
TipRanksApr 4 02:00 ET
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript
Yahoo FinanceApr 1 14:17 ET
Earnings Call Summary | Inventiva(IVA.US) Q4 2023 Earnings Conference
The following is a summary of the Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript:Financial Performance:Inventiva reported Q4 revenues of €17.5 million, a rise of 40% compared to the previous ye
moomoo AIMar 28 11:38 ET · Conference Call
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
TipRanksMar 28 10:10 ET
Inventiva Announces the Nomination of Andre Turenne as Director
Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors.
GlobeNewswireMar 28 03:00 ET
Inventiva SA ADR Announces Optimistic 2023 Results
TipRanksMar 27 17:30 ET
Inventiva GAAP EPS of -€2.43, Revenue of €17.48M
Seeking AlphaMar 27 16:06 ET
Inventiva FY23 €(2.43) Vs €(1.31) YoY; Revenues For 2023 Amounted To €17.5 Million, Up By 43.4%, Compared To €12.2 Million In 2022
Key financial results for the full year of 2023As of December 31, 2023, the Company's cash and cash equivalents amounted to €26.9 million, short-term deposits to €0.01 million, and long-term deposit t
BenzingaMar 27 16:03 ET
Inventiva 2023 Rev EUR17.5M >IVA.FR
Inventiva 2023 Rev EUR17.5M >IVA.FR
Dow JonesMar 27 16:01 ET
Inventiva Estimated Cash Runway Until Beginning of 3Q >IVA.FR
Inventiva Estimated Cash Runway Until Beginning of 3Q >IVA.FR
Dow JonesMar 27 16:01 ET
Inventiva Announces the Schedule of Publication and Presentation of Its 2023 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm
GlobeNewswireMar 22 16:00 ET
Promising Phase 2 Results Bolster Buy Rating for Inventiva's Lanifibranor in Type 2 Diabetes and MASH Treatment
TipRanksMar 20 08:25 ET
HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $22 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Inventiva with a Buy and maintains $22 price target.
Analyst UpgradesMar 20 08:17 ET
Inventiva's Lanifibranor Shows Promise in NASH and T2D Treatment: A Buy Rating Justified
TipRanksMar 19 13:25 ET
COIN, HUT and WNW Among Pre-market Losers
Seeking AlphaMar 19 08:44 ET
No Data
No Data